CapsoVision, Inc
CVNasdaq
$6.71
↑ +5.0%Jul 17 close · end-of-day
Price
1Y↑ +41.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$318.4M
Enterprise Value
$318.4M
P/E
5.1
P/S
23.5
P/B
15.7
EV/EBITDA
—
PEG
—
FCF Yield
-7.5%
Dividend Yield
—
Revenue (TTM)
$13.6M
Net Income (TTM)
-$27.0M
Free Cash Flow (TTM)
-$24.0M
Gross Margin
51.7%
Operating Margin
-200.7%
Net Margin
-198.9%
ROE
-133.4%
ROIC
-106.4%
Debt / Equity
—
Net Cash
—
Return 1Y
+42.8%
Company profile
We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We were incorporated under the laws of the State of Delaware on August 1, 2005, under the name “Capso Vision, Inc.” and changed our name to CapsoVision, Inc. on May 31, 2016. Our principal executive office is located in Saratoga, CA.
- CEO
- Kang-Huai Wang
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 90
- Headquarters
- California
- Website
- capsovision.com
Management & directors
- Atkinson Douglas PatrickHead of Global Sales
- Petersen Rebecca AnnDirector of Clinical Affairs
- Wang Kang-HuaiSee Remarks
Roles derived from SEC Form 4 filings.
Earnings
CV Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.8M↑ +0.3%
Diluted EPS-$0.15↓ -94.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2024 | FY2025 |
|---|---|---|
| Revenue | $11.8M | $13.6M |
| Gross profit | $6.4M | $7.2M |
| Operating income | -$19.9M | -$25.5M |
| Net income | -$19.9M | -$25.3M |
| Diluted EPS | -$9.85 | -$1.03 |
| Operating cash flow | -$20.1M | -$22.9M |
| Free cash flow | -$20.2M | -$23.0M |
| Gross margin | 54.2% | 52.9% |
| Operating margin | -169.4% | -188.3% |
| Net margin | -169.3% | -186.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8M | $3.0M | — | $2.8M | $3.3M | $3.5M | $3.9M | $2.8M |
| Gross profit | $1.6M | $1.7M | — | $1.5M | $1.8M | $1.9M | $2.0M | $1.3M |
| Operating income | -$5.3M | -$5.8M | — | -$5.4M | -$4.7M | -$8.0M | -$7.5M | -$7.1M |
| Net income | -$5.3M | -$5.8M | -$4.6M | -$5.4M | -$4.6M | -$7.9M | -$7.4M | -$7.0M |
| Diluted EPS | -$2.58 | -$2.79 | — | -$2.49 | -$2.02 | -$0.17 | $3.65 | -$0.15 |
| Operating cash flow | — | -$7.1M | — | -$5.0M | -$4.5M | -$5.7M | -$7.7M | -$6.1M |
| Free cash flow | — | -$7.1M | — | -$5.0M | -$4.6M | -$5.7M | -$7.7M | -$6.1M |
| Gross margin | 56.0% | 55.9% | — | 53.7% | 54.6% | 54.1% | 49.9% | 47.6% |
| Operating margin | -185.4% | -195.7% | — | -193.4% | -140.3% | -226.7% | -190.5% | -254.0% |
| Net margin | -185.2% | -195.3% | — | -193.1% | -139.5% | -223.9% | -188.7% | -251.9% |
Company news
May 14, 2026
Apr 30, 2026
Apr 24, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-08 | HARARI ELIYAHOU ET AL | Buy | 81,300 | $6.09 | $495,117.00 | filing |
| 2026-06-30 | Tsai Chen Lung | Option exercise | 2,022 | $7.58 | $15,326.76 | filing |
| 2026-06-30 | Kuo Hui Ying | Option exercise | 2,022 | $7.58 | $15,326.76 | filing |
| 2026-06-30 | King Wen-Herng Henry | Option exercise | 2,022 | $7.58 | $15,326.76 | filing |
| 2026-06-30 | Harari Michele | Option exercise | 2,022 | $7.58 | $15,326.76 | filing |
| 2026-06-30 | GOUW JULIA S | Option exercise | 2,022 | $7.58 | $15,326.76 | filing |
| 2026-06-30 | Imperial Joanne Carol | Option exercise | 2,022 | $7.58 | $15,326.76 | filing |
| 2026-06-26 | HARARI ELIYAHOU ET AL | Buy | 13,850 | $7.35 | $101,811.35 | filing |
| 2026-06-08 | Imperial Joanne Carol | Sale | 1,200 | $7.16 | $8,586.60 | filing |
| 2026-05-05 | Atkinson Douglas Patrick· Head of Global Sales | Option exercise | 34,786 | $0.57 | $19,692.35 | filing |
| 2026-05-04 | Atkinson Douglas Patrick· Head of Global Sales | Option exercise | 30,030 | $0.37 | $10,999.99 | filing |
| 2026-05-04 | Atkinson Douglas Patrick· Head of Global Sales | Option exercise | 36,036 | $0.29 | $10,317.11 | filing |
| 2026-05-04 | Atkinson Douglas Patrick· Head of Global Sales | Option exercise | 6,505 | $0.57 | $3,682.48 | filing |
| 2025-12-31 | Imperial Joanne Carol | Option exercise | 2,887 | $10.69 | $30,862.03 | filing |
| 2025-12-31 | Harari Michele | Option exercise | 2,887 | $10.69 | $30,862.03 | filing |
| 2025-12-31 | GOUW JULIA S | Option exercise | 2,887 | $10.69 | $30,862.03 | filing |
| 2025-12-31 | King Wen-Herng Henry | Option exercise | 2,887 | $10.69 | $30,862.03 | filing |
| 2025-12-31 | Kuo Hui Ying | Option exercise | 2,887 | $10.69 | $30,862.03 | filing |
| 2025-12-31 | Tsai Chen Lung | Option exercise | 2,887 | $10.69 | $30,862.03 | filing |
| 2025-08-18 | Petersen Rebecca Ann· Director of Clinical Affairs | Option exercise | 24,834 | $0.37 | $9,096.69 | filing |
| 2025-07-03 | Tsai Chen Lung | Buy | 20 | $4.17 | $83.40 | filing |
| 2025-07-03 | HARARI ELIYAHOU ET AL | C | 3,186,904 | — | — | filing |
| 2025-07-03 | HARARI ELIYAHOU ET AL | C | 517,759 | — | — | filing |
| 2025-07-03 | HARARI ELIYAHOU ET AL | C | 517,759 | — | — | filing |
| 2025-07-03 | HARARI ELIYAHOU ET AL | C | 3,186,904 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.